Gene Expression Profiling For Identification, Monitoring And Treatment Of Multiple Sclerosis
The present invention provides methods of characterizing multiple sclerosis pr inflammatory conditions associated with multiple sclerosis using gene expression profiling.
1 .- 18 . (canceled)
19 . A method of characterizing multiple sclerosis or an inflammatory condition related to multiple sclerosis in a subject, based on a sample from the subject, the sample providing a source of RNAs, the method comprising:
determining a quantitative measure of the amount of at least one a constituent of Table 5 as a distinct RNA constituent, wherein such measure is obtained under measurement conditions that are substantially repeatable.
20 . The method of claim 19 , wherein said constituent is HLDRA.
21 . The method of claim 20 , further comprising determining a quantitative measure of at least one constituent selected from the group consisting of ITGAL, CASP9, NFKBIB, STAT2, NFKB1, ITGAM, ITGAL, CD4, IL1B, HSPA1A, ICAM1, IF116, or TGFBR2.
22 . The method of claim 21 , wherein the constituents distinguish from a normal and a MS-diagnoses subject with at least 75% accuracy.
23 . The method of claim 19 , wherein said constituent is CASP9.
24 . The method of claim 23 , further comprising determining a quantitative measure of at least one constituent selected from the group consisting of VEGFB, CD14, or JUN.
25 . The method of claim 24 , wherein the constituents distinguish from a normal and a MS-diagnoses subject with at least 75% accuracy.
26 . The method of claim 19 , wherein said constituent is ITGAL
27 . The method of claim 25 , further comprising determining a quantitative measure of at least one constituent selected from the group consisting of P13, ITGAM, TGFBR2
28 . The method of claim 20 , wherein the constituents distinguish from a normal and a MS-diagnoses subject with at least 75% accuracy.
29 . The method of claim 19 , wherein said constituent is STAT3
30 . The method of claim 29 , further comprising determining a qualitative measure of CD14.
31 . The method of claim 30 , wherein the constituents distinguish from a normal and a MS-diagnoses subject with at least 75% accuracy.
32 . The method of claim 19 , comprising determining a qualitative measure of three constituents in any combination shown on Table 7.
33 . The method of claim 19 , wherein the subject has a presumptive sign of a multiple sclerosis selected from the group consisting of altered sensory, motor, visual or proprioceptive system with at least one of numbness or weakness in one or more limbs, often occurring on one side of the body at a time or the lower half of the body, partial or complete loss of vision, frequently in one eye at a time and often with pain during eye movement, double vision or blurring of vision, tingling or pain in numb areas of the body, electric-shock sensations that occur with certain head movements, tremor, lack of coordination or unsteady gait, fatigue, dizziness, muscle stiffness or spasticity, slurred speech, paralysis, problems with bladder, bowel or sexual function, and mental changes such as forgetfulness or difficulties with concentration, relative to medical standards.
34 . A method according to claim 33 , wherein the multiple sclerosis or inflammatory condition related to multiple sclerosis is from an autoimmune condition, an environmental condition, a viral infection, a bacterial infection, a eukaryotic parasitic infection, or a fungal infection.
35 . A method for determining a profile data set according to claim 19 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than five percent.
36 . The method of claim 19 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than three percent.
37 . The method of claim 19 , wherein efficiencies of amplification for all constituents are substantially similar.
38 . The method of claim 19 , wherein the efficiency of amplification for all constituents is within two percent.
39 . The method of claim 19 , wherein the efficiency of amplification for all constituents is 15 less than one percent.
40 .- 41 . (canceled)